At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating sorafenib tosylate, microarray analysis, and 7 other interventions for Adenocarcinoma of the Prostate and 2 related conditions. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients with prostate cancer may help doctors learn more about changes that occur in DNA after treatment with sorafenib tosylate
Study Details
Timeline
Interventions
Given PO
Correlative studies
Correlative studies
Correlative studies
Correlative studies
Undergo prostatectomy
Correlative studies
Correlative studies
Correlative studies